Inagaki N, Miura T, Ohira K, Nagai H, Xu Q A, Koda A
Department of Pharmacology, Gifu Pharmaceutical University, Japan.
J Pharmacobiodyn. 1990 May;13(5):272-7. doi: 10.1248/bpb1978.13.272.
Effect of CV-3988, a specific antagonist against platelet activating factor (PAF), on homologous passive cutaneous anaphylaxis (PCA) elicited in the mouse ear was investigated. PAF caused a potent increase in vascular permeability in the mouse ear. The potency was slightly lower than that of serotonin but higher than those of histamine, leukotriene (LT) C4, LTD4, prostaglandin (PG) E1 and PGE2 on a weight basis. The increased vascular permeability caused by PAF was inhibited by CV-3988 in a dose-dependent manner. CV-3988 did not affect the increase in vascular permeability caused by histamine or serotonin. IgG1 antibody-mediated PCA in the mouse ear was inhibited by CV-3988, although it did not affect IgE antibody-mediated PCA. These results suggest a possibility that PAF might be involved in IgG1 antibody-mediated PCA in the mouse.
研究了血小板活化因子（PAF）特异性拮抗剂CV-3988对小鼠耳部同源被动皮肤过敏反应（PCA）的影响。PAF可使小鼠耳部血管通透性显著增加。按重量计算，其效力略低于5-羟色胺，但高于组胺、白三烯（LT）C4、LTD4、前列腺素（PG）E1和PGE2。CV-3988可剂量依赖性地抑制PAF引起的血管通透性增加。CV-3988不影响组胺或5-羟色胺引起的血管通透性增加。CV-3988可抑制小鼠耳部IgG1抗体介导的PCA，尽管它不影响IgE抗体介导的PCA。这些结果提示PAF可能参与小鼠IgG1抗体介导的PCA。
